Quick Answer
Alpha-Lipoic Acid Metabolic Markers Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Results: All three compounds were associated with shifts in microbial composition compared to the HFD-only group.
Key Takeaways
- 01Results: All three compounds were associated with shifts in microbial composition compared to the HFD-only group. [Kim HJ (2026)]
- 02Background/Objectives: This exploratory study ( n = 6 per group) investigated the associations between supplementation with α-lipoic acid (AL), betaine (BT), and L-carnitine (LC) and gut microbiota composition in a high-fat diet (HFD)-induced obesity mouse model. [Kim HJ (2026)]
- 03Methods: Four-week-old male C57BL/6J mice were fed a control diet (10% fat), HFD (60% fat), or HFD supplemented with AL, BT, or LC (300 mg/kg BW/day) for nine weeks. [Kim HJ (2026)]
- 04Conclusion These findings clearly demonstrate that ALA confers manifold hepatoprotective effects against CSD-induced dysfunction by significantly restoring redox balance, decreasing hepatic inflammation, suppressing apoptotic and ferroptotic signaling, thereby successfully preserving metabolic activity. [Chang HM (2026)]
The current Migaku evidence database contains 2 reusable source documents for Alpha-Lipoic Acid Metabolic Markers Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Results: All three compounds were associated with shifts in microbial composition compared to the HFD-only group. [Kim HJ (2026); evidence level 4]
- Background/Objectives: This exploratory study ( n = 6 per group) investigated the associations between supplementation with α-lipoic acid (AL), betaine (BT), and L-carnitine (LC) and gut microbiota composition in a high-fat diet (HFD)-induced obesity mouse model. [Kim HJ (2026); evidence level 4]
- Methods: Four-week-old male C57BL/6J mice were fed a control diet (10% fat), HFD (60% fat), or HFD supplemented with AL, BT, or LC (300 mg/kg BW/day) for nine weeks. [Kim HJ (2026); evidence level 4]
- Conclusion These findings clearly demonstrate that ALA confers manifold hepatoprotective effects against CSD-induced dysfunction by significantly restoring redox balance, decreasing hepatic inflammation, suppressing apoptotic and ferroptotic signaling, thereby successfully preserving metabolic activity. [Chang HM (2026); evidence level 4]
- Objective Chronic sleep deprivation (CSD) is a major public health issue that causes metabolic dysfunction by disrupting redox homeostasis and triggering hepatic inflammation. [Chang HM (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources